Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3212) 3212
Newspaper Article (125) 125
Newsletter (88) 88
Book Chapter (40) 40
Magazine Article (24) 24
Dissertation (2) 2
Publication (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adalimumab (2879) 2879
humans (2522) 2522
science & technology (2434) 2434
life sciences & biomedicine (2386) 2386
female (1565) 1565
male (1469) 1469
infliximab (1258) 1258
adult (1229) 1229
middle aged (1193) 1193
tumor necrosis factor-alpha - antagonists & inhibitors (1130) 1130
treatment outcome (1002) 1002
etanercept (835) 835
antibodies, monoclonal - therapeutic use (815) 815
rheumatology (732) 732
rheumatoid arthritis (723) 723
antibodies, monoclonal, humanized (695) 695
arthritis, rheumatoid - drug therapy (664) 664
dermatology (575) 575
antirheumatic agents - therapeutic use (570) 570
psoriasis (569) 569
aged (564) 564
antibodies, monoclonal, humanized - therapeutic use (531) 531
care and treatment (531) 531
adalimumab - therapeutic use (513) 513
drug therapy (473) 473
gastroenterology & hepatology (453) 453
antibodies, monoclonal - adverse effects (440) 440
biological and medical sciences (433) 433
tumor necrosis factor (432) 432
medical sciences (430) 430
crohn disease - drug therapy (413) 413
psoriasis - drug therapy (406) 406
severity of illness index (400) 400
anti-inflammatory agents - therapeutic use (397) 397
antibodies, monoclonal - administration & dosage (386) 386
arthritis (379) 379
retrospective studies (375) 375
adalimumab - administration & dosage (373) 373
monoclonal antibodies (368) 368
pharmacology & pharmacy (367) 367
dosage and administration (357) 357
crohn's disease (355) 355
young adult (353) 353
tumor necrosis factor-tnf (351) 351
antirheumatic agents - adverse effects (344) 344
immunoglobulin g - therapeutic use (342) 342
receptors, tumor necrosis factor - therapeutic use (338) 338
medicine & public health (327) 327
antirheumatic agents - administration & dosage (313) 313
adolescent (299) 299
analysis (298) 298
inflammatory bowel disease (293) 293
antibodies, monoclonal, humanized - administration & dosage (292) 292
patients (290) 290
drug therapy, combination (288) 288
antibodies, monoclonal, humanized - adverse effects (281) 281
anti-inflammatory agents - administration & dosage (280) 280
research (266) 266
ulcerative colitis (261) 261
methotrexate (258) 258
infliximab - therapeutic use (254) 254
adalimumab - adverse effects (253) 253
rheumatoid factor (250) 250
abridged index medicus (248) 248
time factors (241) 241
risk factors (233) 233
follow-up studies (229) 229
clinical trials (228) 228
drug administration schedule (228) 228
anti-inflammatory agents - adverse effects (227) 227
immunology (219) 219
dose-response relationship, drug (207) 207
health aspects (203) 203
methotrexate - therapeutic use (199) 199
prospective studies (192) 192
pharmacology. drug treatments (191) 191
medical research (190) 190
internal medicine (186) 186
tumor necrosis factor-alpha - immunology (178) 178
biological products (177) 177
immunoglobulin g - adverse effects (176) 176
immunosuppressive agents - therapeutic use (176) 176
quality of life (174) 174
arthritis, psoriatic - drug therapy (172) 172
child (171) 171
remission induction (170) 170
tnf inhibitors (170) 170
medicine, experimental (167) 167
musculoskeletal diseases (166) 166
general & internal medicine (164) 164
diseases of the osteoarticular system (163) 163
medicine, general & internal (163) 163
tumors (163) 163
double-blind method (162) 162
inflammation (162) 162
tumor necrosis factor-α (159) 159
complications and side effects (157) 157
psoriatic arthritis (156) 156
cohort studies (154) 154
colitis, ulcerative - drug therapy (153) 153
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3386) 3386
German (37) 37
Spanish (36) 36
Japanese (19) 19
Russian (15) 15
French (12) 12
Hungarian (12) 12
Italian (9) 9
Portuguese (9) 9
Korean (8) 8
Danish (4) 4
Chinese (2) 2
Turkish (2) 2
Croatian (1) 1
Polish (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality
by Ingram, J.R and Woo, P.N and Chua, S.L and Ormerod, A.D and Desai, N and Kai, A.C and Hood, K and Burton, T and Kerdel, F and Garner, S.E and Piguet, V
British journal of dermatology (1951), ISSN 0007-0963, 05/2016, Volume 174, Issue 5, pp. 970 - 978
Life Sciences & Biomedicine | Dermatology | Science & Technology | Norgestrel - administration & dosage | Wound Closure Techniques | Etanercept - administration & dosage | Administration, Oral | Cyproterone Acetate - administration & dosage | Dermatologic Agents - administration & dosage | Humans | Hidradenitis Suppurativa - drug therapy | Treatment Outcome | Gentamicins - administration & dosage | Infliximab - administration & dosage | Adalimumab - administration & dosage | Clindamycin - administration & dosage | Quality of Life | Adult | Androgen Antagonists - administration & dosage | Ethinyl Estradiol - administration & dosage | Anti-Bacterial Agents - administration & dosage | Index Medicus | Systematic Review | Reviews
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
by Fleischmann, Roy, Prof and Mysler, Eduardo, MD and Hall, Stephen, MD and Kivitz, Alan J, MD and Moots, Robert J, Prof and Luo, Zhen, PhD and DeMasi, Ryan, MD and Soma, Koshika, MD and Zhang, Richard, PhD and Takiya, Liza, PharmD and Tatulych, Svitlana, MD and Mojcik, Christopher, MD and Krishnaswami, Sriram, PhD and Menon, Sujatha, PhD and Smolen, Josef S, Prof and ORAL Strategy investigators and ORAL Strategy Investigators
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10093, pp. 457 - 468
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Adalimumab - adverse effects | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Piperidines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Treatment Outcome | Methotrexate - adverse effects | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Methotrexate - administration & dosage | Rheumatoid factor | Care and treatment | Analysis | Clinical trials | Arthritis | Pharmaceutical industry | Methotrexate | Rheumatology | Patients | Evidence-based medicine | Studies | Rheumatoid arthritis | Monoclonal antibodies | Rheumatism | TNF inhibitors | Janus kinase | Tumor necrosis factor-TNF | Safety | Drug therapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial
by Hørslev-Petersen, Kim and Hetland, Merete Lund and Junker, Peter and Pødenphant, Jan and Ellingsen, Torkell and Ahlquist, Palle and Lindegaard, Hanne and Linauskas, Asta and Schlemmer, Annette and Dam, Mette Yde and Hansen, Ib and Horn, Hans Christian and Ammitzbøll, Christian Gytz and Jørgensen, Anette and Krintel, Sophine B and Raun, Johnny and Johansen, Julia S and Østergaard, Mikkel and Stengaard-Pedersen, Kristian and OPERA Study-Grp and OPERA Study-Group and OPERA study-group
Annals of the rheumatic diseases, ISSN 0003-4967, 04/2014, Volume 73, Issue 4, pp. 654 - 661
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Triamcinolone - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Triamcinolone - adverse effects | Arthritis, Rheumatoid - drug therapy | Antirheumatic Agents - adverse effects | Adult | Female | Drug Therapy, Combination | Triamcinolone - therapeutic use | Arthritis, Rheumatoid - physiopathology | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Remission Induction | Methotrexate - adverse effects | Injections, Intra-Articular | Quality of Life | Methotrexate - administration & dosage | Aged | Adalimumab | Rheumatoid arthritis | Dosage and administration | Research | Methotrexate | Drug therapy | Triamcinolone | Studies | Pain | Clinical medicine | Quality of life | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
by Khanna, Reena, MD and Bressler, Brian, Prof and Levesque, Barrett G, MD and Zou, Guangyong, Prof and Stitt, Larry W, MSc and Greenberg, Gordon R, Prof and Panaccione, Remo, Prof and Bitton, Alain, Prof and Paré, Pierre, Prof and Vermeire, Séverine, Prof and D'Haens, Geert, Prof and MacIntosh, Donald, Prof and Sandborn, William J, Prof and Donner, Allan, Prof and Vandervoort, Margaret K, MSc and Morris, Joan C, MHSc and Feagan, Brian G, Prof and REACT Study Investigators
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 10006, pp. 1825 - 1834
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Azathioprine - administration & dosage | Azathioprine - therapeutic use | Immunosuppression - methods | Humans | Mercaptopurine - administration & dosage | Male | Treatment Outcome | Methotrexate - therapeutic use | Antimetabolites - therapeutic use | Infliximab - therapeutic use | Infliximab - administration & dosage | Antimetabolites - administration & dosage | Crohn Disease - therapy | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Mercaptopurine - therapeutic use | Adult | Female | Methotrexate - administration & dosage | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Clinical trials | Gastrointestinal diseases | Immunotherapy | Algorithms | Surgery | Mortality | Gastroenterology | Drug therapy | Crohns disease | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
by Warren, Richard B and Smith, Catherine H and Yiu, Zenas Z.N and Ashcroft, Darren M and Barker, Jonathan N.W.N and Burden, A. David and Lunt, Mark and McElhone, Kathleen and Ormerod, Anthony D and Owen, Caroline M and Reynolds, Nick J and Griffiths, Christopher E.M and BADBIR Study Grp
Journal of investigative dermatology, ISSN 0022-202X, 11/2015, Volume 135, Issue 11, pp. 2632 - 2640
Life Sciences & Biomedicine | Dermatology | Science & Technology | Biological Therapy - methods | Prospective Studies | Biological Products - pharmacokinetics | Etanercept - administration & dosage | Humans | Middle Aged | Psoriasis - diagnosis | Male | Infliximab - administration & dosage | Infliximab - pharmacokinetics | Dose-Response Relationship, Drug | Societies, Medical | Etanercept - pharmacokinetics | Adult | Female | Registries | Ustekinumab - administration & dosage | Psoriasis - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Maximum Tolerated Dose | Adalimumab - administration & dosage | Ustekinumab - pharmacokinetics | Biological Products - administration & dosage | Cohort Studies | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration Database
by JOHN D. CARTER and ANIL LADHANI and LOUIS R. RICCA and JOANNE VALERIANO and FRANK B. VASEY
Journal of rheumatology, ISSN 0315-162X, 03/2009, Volume 36, Issue 3, pp. 635 - 641
Pregnancy | Tumor necrosis factor antagonists | Safety | Life Sciences & Biomedicine | Rheumatology | Science & Technology | Biological and medical sciences | Diseases of the osteoarticular system | Medical sciences | United States - epidemiology | Prenatal Exposure Delayed Effects | Abnormalities, Drug-Induced - epidemiology | Humans | Antibodies, Monoclonal - adverse effects | Immunoglobulin G - adverse effects | Incidence | Antibodies, Monoclonal, Humanized | Etanercept | Infliximab | Receptors, Tumor Necrosis Factor | Antirheumatic Agents - adverse effects | Female | Registries | Adalimumab | Tumor Necrosis Factor-alpha - antagonists & inhibitors | United States Food and Drug Administration | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Role of quantitative clinical pharmacology in pediatric approval and labeling
by Mehrotra, Nitin and Bhattaram, Atul and Earp, Justin C and Florian, Jeffry and Krudys, Kevin and Lee, Jee Eun and Lee, Joo Yeon and Liu, Jiang and Mulugeta, Yeruk and Yu, Jingyu and Zhao, Ping and Sinha, Vikram
Drug metabolism and disposition, ISSN 0090-9556, 07/2016, Volume 44, Issue 7, pp. 924 - 933
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Age Factors | Esomeprazole - administration & dosage | Humans | Seizures - drug therapy | Child, Preschool | Anticonvulsants - administration & dosage | Infant | Adolescent Development | Drug Approval | Anti-HIV Agents - administration & dosage | Dose-Response Relationship, Drug | Drug Dosage Calculations | Proton Pump Inhibitors - administration & dosage | Vigabatrin - administration & dosage | Adalimumab - pharmacokinetics | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Child Development | Gastroesophageal Reflux - drug therapy | Pharmaceutical Preparations - administration & dosage | Child | Infant, Newborn | Anticonvulsants - pharmacokinetics | Esomeprazole - pharmacokinetics | Drug Labeling | Pharmaceutical Preparations - metabolism | Adalimumab - administration & dosage | Proton Pump Inhibitors - pharmacokinetics | Models, Biological | Vigabatrin - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Crohn Disease - drug therapy | Adolescent | HIV Infections - drug therapy | Pharmacokinetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
by Mease, Philip and Hall, Stephen and FitzGerald, Oliver and van der Heijde, Désirée and Merola, Joseph F and Avila-Zapata, Francisco and Cieślak, Dorota and Graham, Daniela and Wang, Cunshan and Menon, Sujatha and Hendrikx, Thijs and Kanik, Keith S
The New England journal of medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 16, pp. 1537 - 1550
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Disability Evaluation | Piperidines - administration & dosage | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Adalimumab - adverse effects | Dose-Response Relationship, Drug | Janus Kinases - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Adalimumab - therapeutic use | Pyrroles - administration & dosage | Arthritis, Psoriatic - drug therapy | Piperidines - adverse effects | Pyrimidines - adverse effects | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Antirheumatic Agents - therapeutic use | Care and treatment | Antirheumatic agents | Research | Management | Patients | Psoriatic arthritis | Herpes zoster | Inhibitor drugs | Psoriasis | Cytokines | Rheumatology | Arthritis | Joint diseases | Monoclonal antibodies | TNF inhibitors | Janus kinase | Tumor necrosis factor-TNF | Drug therapy | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights